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Abstract 
 
The emergence of variant Creutzfeld-Jakob disease (vCJD), following on from the 
bovine spongiform encephalopathy (BSE) epidemic, led to concerns about the 
potential risk of iatrogenic transmission of disease by blood transfusion and the 
introduction of costly control measures to protect blood supplies. We previously 
reported preliminary data demonstrating the transmission of BSE and natural scrapie 
by blood transfusion in sheep. The final results of this experiment, reported here, give 
unexpectedly high transmission rates by transfusion of 36% for BSE and 43% for 
scrapie. A proportion of BSE-infected tranfusion recipients (3/8) survived for up to 7 
years without showing clinical signs of disease. The majority of transmissions 
resulted from blood collected from donors at >50% of the estimated incubation 
period. The high transmission rates and relatively short and consistent incubation 
periods in clinically positive recipients suggest that infectivity titres in blood were 
substantial and/or that blood transfusion is an efficient method of transmission. This 
experiment has established the value of using sheep as a model for studying 
transmission of vCJD by blood products in humans.  
 
Introduction 
 
Transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases, 
which include Creutzfeld-Jakob disease (CJD) in man, scrapie in sheep and bovine 
spongiform encephalopathy (BSE) in cattle. A new variant of CJD (termed vCJD) 
was recognised in the United Kingdom in the mid-1990s, apparently as a result of 
transmission of BSE to humans1. To date, there have been 166 cases of vCJD 
recorded in the UK, as well as several cases in other countries. Human TSEs are 
characterised by long asymptomatic incubation periods (usually several years), and 
there is no reliable test for detecting infection before the onset of clinical disease. It is 
not known how many people in the UK harbour vCJD, although estimates based on 
screening of tonsil and appendix samples suggest there could be up to 40002. These 
infected individuals pose a risk of human-to-human transmission via blood 
transfusion or contaminated surgical instruments. 
 
In patients with vCJD there is widespread replication of the infectious agent and 
deposition of PrPSc (disease-associated form of prion protein) in lymphoreticular 
tissues such as the tonsil, spleen and lymph nodes, in contrast to sCJD, where 
lymphoreticular involvement is minimal3. The fact that lymphocytes continually 
recirculate between blood and lymphoreticular tissues strongly suggests that the blood 
of vCJD patients is likely to be infectious. Data from rodent TSE models had shown 
that the highest levels of infectivity in blood were associated with leukocytes and, to a 
lesser extent, plasma4. As a result, costly control measures such as leucodepletion 
(filtration of blood and blood products to remove leukocytes) and importation of 
plasma were introduced to protect UK blood supplies, despite the limited data that 
were then available to judge the size of the risk and the efficacy of the control 
measures. 
The potential for using sheep as a model for studying the risks of vCJD transmission 
by blood transfusion was highlighted by the similarity between the distribution of 
infectivity and PrPSc in sheep infected with TSEs and humans infected with vCJD5-7. 
One factor limiting the successful transmission of TSEs by blood in rodent models 
was the small volumes of blood that could be injected. In contrast, the relative 
similarity in size of sheep and humans means that volumes of blood comparable to 
those used in human transfusion practice can be collected from and transfused into 
sheep. Using this model, we previously reported preliminary results showing that both 
BSE and natural scrapie could be transmitted between sheep by blood transfusion8,9. 
Although scrapie is not thought to be transmissible to humans, it was included as a 
representative of infection acquired under field conditions, which may give different 
results to those obtained from experimentally infected animals. Our blood transfusion 
experiment in sheep is complete after nine years, and this paper presents the full data 
from the study. The overall transmission rates for both scrapie and BSE are 
surprisingly high when factors such as the stage of infection and genetic background 
are taken into account, suggesting that blood transfusion represents an efficient route 
of transmission.  
 
Materials and Methods 
 
Donor and recipient sheep 
 
PrP genotypes of all sheep were confirmed by sequencing the coding region of the 
PrP gene10, and are represented by single letter amino acid code for codons 136, 154 
and 171, which have been linked to scrapie susceptibility (e.g. ARQ represents 
alanine, arginine and glutamine respectively at codons 136, 154 and 171). 
 
All donor sheep were from the Edinburgh NPU Cheviot flock, which has endemic 
natural scrapie.  The recipient sheep (including scrapie negative control donors) were 
Cheviots derived from the DEFRA scrapie-free (DEFRA/SF) flock of New Zealand 
origin. Transfusion recipients, positive and negative controls were housed in a 
purpose-built isolation unit on a different site to the donors, with strict procedures in 
place to minimise the risk of cross-contamination between groups, as described9. The 
sheep were scored at weekly intervals for clinical signs of TSEs, and killed when they 
reached humane end points agreed with the Home Office. For experimentally 
inoculated animals (BSE donors, positive controls and transfusion recipients), the 
incubation period (IP) in clinically positive sheep was defined as the period between 
the date of inoculation and the date of death. For scrapie-exposed donors, the IP in 
clinically positive sheep was defined as the age at death (i.e. they were assumed to 
have become infected immediately after birth). 
 
Blood collection and transfusion 
 
Procedures for blood collection/transfusion were as previously described9. Briefly, 
venous blood (450-500ml = 1 unit) was collected into sterile collection bags (NBPI-
Fresenius, Emmer-Compascuum, NL) containing citrate phosphate dextrose adenine 
solution as anticoagulant. From donors that were about to be euthanased, 2 units were 
collected just before post-mortem, while from donors that were to be left alive, 
separate collections of 1 unit were made at least 28 days apart. However, for practical 
reasons it was not always possible to collect 2 units of blood from every donor sheep. 
In most cases where 2 units of blood were obtained, one was transfused as whole 
blood (without leucodepletion) and the other was used to prepare a buffy coat 
fraction.  
 
BSE blood transfusions 
 
Fifteen sheep experimentally inoculated either orally (14) or intracerebrally (1) with 
5g or 0.05g respectively of BSE-infected cattle brain homogenate were used as blood 
donors. The donor PrP genotypes were ARQ/ARQ (n = 3), ARQ/AHQ (n = 5) or 
AHQ/AHQ (n = 7), which are resistant to natural scrapie in the NPU flock, but 
produce the shortest IPs after inoculation with BSE. Two sheep previously reported as 
donors9 were excluded from the study (along with their recipients) when re-
genotyping showed them to be ARQ/ARR and VRQ/AHQ respectively, genotypes 
which result in relative resistance to oral infection with BSE.  
 
Eleven donor sheep provided blood for transfusion at the preclinical stage of 
infection. Eight of these were culled at the time of donation as part of a separate time 
course pathogenesis experiment. The remaining three pre-clinical donors went on to 
develop clinical signs of BSE, with respective IPs of 629, 761 and 2131 days post 
infection.  Four sheep were used as blood donors once they had developed clinical 
signs of BSE at 561-671 days post infection. PrPSc deposits in brain and/or in 
peripheral tissues were confirmed in all clinically affected donors by 
immunohistochemistry (IHC). In two donors culled at the pre-clinical stage, sparse 
PrPSc deposits were found in only one tissue in each sheep: Peyer’s patch (58x81) and 
dorsal root ganglion (60x49). However, a negative result was obtained when the same 
tissues were immunostained in another laboratory. There were 15 ARQ/ARQ 
recipients of whole blood and 7 ARQ/ARQ recipients of buffy coat from BSE-
infected donors. Figure 1 gives a summary of the experimental design, while details 
of the donor and recipient sheep are in Table 1. 
 
Scrapie blood transfusions 
 
The donors for this experiment were ten VRQ/VRQ and one VRQ/ARQ Cheviot 
sheep from the Edinburgh NPU flock, where sheep of these genotypes show a disease 
incidence approaching 100%. Epidemiological and pathological evidence suggests 
that infection occurs around the time of birth. Blood collections were made from 
animals in 3 different age groups (200-250 days, 450-500 days, 700-850 days) to 
represent donors at different pre-clinical stages of disease, as well as from one clinical 
case. Seven donors were culled after developing clinical signs of scrapie at ages 
ranging from 1081 to 1556 days, and were confirmed positive by histopathology and 
IHC. Two donors were culled before the onset of clinical signs at 1197 and 1350 days 
of age respectively, but PrPSc was detected in their tissues by IHC.  Two donors died 
prematurely at 349 and 974 days of age: one was IHC negative, in the other, the 
tissues were too decomposed to allow analysis. There were 21 recipients (all 
VRQ/VRQ PrP genotype) of blood from scrapie-exposed donors; eleven were 
transfused with buffy coat and ten with whole blood. See Figure 1 for a summary of 
the experimental design, and Table 2 for details of donor and recipient sheep. 
 
Positive and negative controls 
 
Seven ARQ/AHQ and three ARQ/ARQ sheep were infected intravenously with 0.2g 
of the same BSE-infected cattle brain homogenate as given orally to the blood donors, 
and served as positive controls. No positive controls were used in the scrapie 
transfusion experiment. As negative controls for the BSE transfusion experiment, 12 
ARQ/ARQ recipients were given transfusions of whole blood (6) or buffy coat (6) 
from 7 uninfected donors (6 ARQ/AHQ, 1 ARQ/ARR). Two recipients died at 633 
days and 1181 days post transfusion respectively, and the remaining 10 recipients 
were culled between 2462 and 2586 days post transfusion. As negative controls for 
the scrapie experiment, 16 VRQ/VRQ sheep received either whole blood (8) or buffy 
coat (8) collected from 8 uninfected VRQ/VRQ donors. There were two intercurrent 
deaths at 397 days and 464 days post transfusion, and the other 14 animals were 
culled between 2052 and 2409 days post transfusion. None of the negative controls 
for the BSE or scrapie experiments showed clinical signs of TSEs and all were IHC 
negative for PrPSc.  
 
PrPSc detection by immunohistochemistry (IHC)  
 
Tissue samples from the brain, spleen, mesenteric lymph node and palatine tonsil of 
the sheep under study were fixed in formaldehyde and processed according to 
standard procedures. Sections were immunolabelled for PrPSc detection by IHC with 
primary antibody R145, which recognizes the 222-226 amino acid sequence of ovine 
PrP11, as described previously12,13.  
 
Results 
 
1) BSE transfusion experiment 
 
A total of five transfusion recipients showed clinical signs of TSEs, and were 
confirmed positive by IHC and/or Western blot (see Table 1 & Figure 2). These 
included two (F19 and D505) out of twelve sheep transfused with whole blood from 
donors in the pre-clinical phase of infection (at 45% and 50% of estimated IP, 
respectively), as reported previously8,9. Two out of three recipients of whole blood 
and one out of two recipients of buffy coat from donors clinically affected by BSE 
developed clinical BSE. The IPs in the five clinically positive recipient sheep ranged 
from 531 to 610 days post transfusion (mean ± SD = 565 ± 35 days), and there was no 
obvious difference in the IPs of those that received blood from pre-clinical or clinical 
donors.  
 
One recipient (D452) of whole blood from a pre-clinical donor died of unrelated 
causes at 1139 days post transfusion, but had PrPSc-positive IHC labelling in brain and 
other tissues. One of three recipients of whole blood (G92) and one of two recipients 
of buffy coat (G61) from clinical donors showed weak PrPSc deposition in the brain 
and lymphoid tissues after being culled at 2003 and 2497 days post transfusion 
respectively, in the absence of clinical signs. Full sequencing of the PrP gene of these 
sheep revealed that they carried an additional proline (P) to leucine (L) substitution at 
codon 16814,15, which appears to be associated with the prolonged survival of these 
infected sheep. The polymorphism was also identified in two recipients of blood from 
a pre-clinical BSE-challenged donor, neither of which showed evidence of infection.  
 
Taking the results for all 22 recipients of blood from BSE-exposed donors, five 
clinical cases and three sheep showing evidence of infection in the absence of clinical 
signs were identified, giving an overall transmission rate of 36%.  
 
One recipient was culled for health reasons at 1444 days post transfusion, two were 
culled with suspected TSE clinical signs at 2480 and 2160 days post transfusion 
respectively, and the remaining clinically negative sheep were culled between 2239 
and 3068 days post transfusion. With one exception, examination of the tissues by 
IHC did not find evidence of infection. The exception (D337) was culled at 3018 days 
post transfusion and showed positive PrPSc labelling in the brain, but with a pattern 
distinct from that observed in other BSE-infected sheep.  The brain PrPSc distribution 
involving major white matter tracts and sparing the dorsal motor nucleus of the vagus 
was similar to that of Nor98 (or “atypical” sheep scrapie) and therefore unlikely to be 
transfusion-related. No other sheep in the present study showed evidence of being 
infected with atypical scrapie. 
 
Out of the ten sheep that were infected intravenously with BSE as positive controls, 
eight developed clinical signs confirmed by IHC, with an average IP of 702 days (± 
61 days standard deviation). The remaining two animals were culled at 2591 days post 
infection and, although not demonstrably clinically affected, IHC showed PrPSc 
deposition in the brains and lymphoid tissues of both animals. These two sheep were 
heterozygous (PL168) for the PrP polymorphism P168L (see above), while the other 
eight were homozygous (PP168). 
 
The PrPSc profile obtained by IHC from BSE positive recipients was the same as that 
found in the orally inoculated donors and in the positive controls16. In addition, 
characteristic BSE glycoform patterns were obtained by Western blot analysis of 
PrPSc positive donor and recipient sheep (data not shown; see9), and inoculation of 
brain homogenates from infected donors and recipients into a panel of inbred mouse 
strains produced IPs and lesion profiles characteristic of BSE (data not shown). Taken 
together, these results confirm that the strain characteristics were not altered following 
transmission via blood. 
 
2) Scrapie transfusion experiment 
 
Four out of ten recipients of whole blood and four out of ten recipients of buffy coat 
from donors in the pre-clinical phase of scrapie infection developed clinical signs of 
scrapie, which were confirmed by positive IHC results. One sheep transfused with 
buffy coat from the single clinical donor was also clinically affected and IHC positive 
(see Table 2 & Figure 2). Four of these cases (F144, F153, F141 & F143) were 
reported previously9. There were four intercurrent deaths at 354, 753, 1237 and 1615 
days post transfusion respectively, and the eight remaining recipients were culled 
between 2329 and 2484 days post transfusion. These twelve animals were clinically 
negative at the time of death, and showed no detectable PrPSc by IHC. Thus, nine out 
of 21 recipients of blood from scrapie-exposed sheep developed clinical scrapie, 
giving an overall transmission rate of 43%.  
 
The majority of confirmed scrapie cases in recipients (n = 7) occurred in the groups 
that received transfusions from donors in the late pre-clinical (>50% of estimated IP) 
or clinical phase of infection. Only 2 out of 9 recipients in these groups remained free 
of infection. The other two positive recipients were in the group of 6 sheep that 
received transfusions from donors at 28-37% of estimated IP, and their IPs were much 
longer than the rest (1101 and 1138 days post transfusion compared to a range of 575-
853 days in recipients of blood from donors at >50% of estimated IP). No disease was 
confirmed in the 6 recipients that received blood from donors at ≤20% of estimated 
IP.  
 
The PrPSc profile obtained from brains of donors and recipients highlighted some 
differences in terms of presence of vascular plaques or glia-associated PrPSc  in 
donors but not in recipients, or vice versa (unpublished data). Such discrepancies were 
interpreted as presence of more than one natural scrapie strain in the flock of origin.  
 
Discussion 
 
The outcome of the blood transfusion experiments showed that two different TSE 
agents, scrapie and BSE, could be efficiently transmitted between sheep by blood 
transfusion, using volumes similar to those employed in human transfusions. The 
overall transmission rates (percentage of all recipients that became infected) were 
36% for BSE and 43% for scrapie. For BSE, the figure was much higher than 
anticipated because three of the eight BSE-infected recipients survived for long 
periods without showing clinical signs, whereas all the scrapie-infected recipients 
identified by IHC were also clinically positive. The greater probability of sub-clinical 
infection in recipients of blood from BSE-exposed donors is largely due to variability 
in the genetic susceptibility to infection among sheep used in the BSE experiment, 
which will be discussed below. The results are consistent with the known facts about 
transmission of vCJD by blood transfusion in humans17. Sixty-six individuals known 
to have received labile blood products from 18 donors who subsequently developed 
vCJD were followed up in an on-going study. Three of these recipients have been 
confirmed clinically and pathologically as vCJD cases, with intervals between 
transfusion and the development of clinical signs ranging from approximately 6½ 
years to 8½ years18-20. Another individual, who died of unrelated causes 5 years post 
transfusion, showed PrPSc deposits in lymphoid tissues but not brain at post mortem, 
and is thought to represent pre-clinical or sub-clinical infection21. These four 
individuals represent 6% of the total recipients, or 12.5% of recipients surviving 
longer than 5 years.  
 
Various factors influence the transmission rate by transfusion in both sheep and 
humans, including: (i) the interval between blood donation and the onset of clinical 
signs in the donors, (ii) genetic variation in susceptibility of donors and recipients, 
and (iii) the blood component transfused.  
 
1) Stage of incubation period of the donors at the time of blood donation. 
 
The effect of the stage of incubation can best be deduced from the results of the 
scrapie transfusion experiment, since the PrP genotype of the sheep used (VRQ/VRQ) 
renders them almost 100% susceptible to natural and experimental infection22.  The 
stage of incubation of the donor has a strong influence on the probability of 
transmission to the recipient (Figure 2). When donations were made at ≤20% of the 
estimated IP, there was no disease transmission, while donations made at >50% of the 
estimated IP produced an 80% transmission rate, with a mean IP of 729 days (SD ± 
99) in the recipients. Blood collected at 28-37% of the estimated IP transmitted 
infection at a lower rate of approximately 33%, and with longer IPs in the recipients 
of >1000 days. The data are consistent with a gradual increase in infectivity in the 
blood, from approximately 30-50% of IP until the clinical phase. 
 
In the BSE transfusion experiment, the correlation between stage of infection and 
transmission is not clear-cut, but shows the same general trend of increasing 
probability of transmission to recipients as infection progresses in the donors (Figure 
2). Possible explanations for the lower transmission rates from pre-clinical BSE-
infected blood donors compared to pre-clinical scrapie-infected donors include:  
a) Variation in susceptibility to infection of both donor and recipient sheep. This 
will be discussed below.  
b) Differences in the pathogenesis of natural scrapie and experimental BSE. 
VRQ/VRQ sheep naturally infected with scrapie have detectable PrPSc 
deposits in lymphoid tissues early after infection (i.e. <50% estimated IP)23,24. 
Time course studies of ARQ/ARQ sheep orally infected with BSE showed that 
PrPSc was not consistently detected in lymphoid tissues before at least 65% of 
the average IP7. If infectivity in blood correlates with its presence in lymphoid 
tissues, this could explain the differences observed in the two transfusion 
experiments.   
 
The probability of transmission from pre-clinical donors is of greatest relevance to the 
human situation. In the case of the four transfusion-related transmissions of vCJD, the 
donors developed clinical signs between 17-42 months after donation. The mean IP 
for vCJD has been estimated to be 16.7 years, with a lower 95% confidence interval 
of approximately 12.4 years25. Therefore, it is likely that the transfusion-related vCJD 
cases resulted from donations made at least half-way through the IP, which is in 
agreement with the data from the sheep experiments. In vCJD cases, the timing of 
detectable lymphoid replication in the pre-clinical stages of disease is unknown; 
therefore it is not clear whether the peripheral pathogenesis more closely resembles 
BSE or natural scrapie in sheep. 
 
2) Effect of genetic variation in susceptibility. 
 
A small proportion of sheep with A136Q171/A136Q171 PrP genotypes do not succumb to 
infection following natural or experimental exposure to scrapie and BSE, or have very 
prolonged incubation periods26-28. The reasons for this variability in response are not 
clearly understood, but it can be predicted to reduce infection rates in both donor and 
recipient sheep in the BSE transfusion experiment. The majority of pre-clinical donor 
sheep (8/11) in the BSE transfusion experiment were killed at, or shortly after, the 
time of donation, and none showed conclusive evidence of infection, although two 
transmitted infection to their respective transfusion recipients. It is potentially 
significant that donors that failed to transmit infection were heterozygous at PrP 
codon 154, while those that did transmit infection were homozygous. Thus, variable 
susceptibility to infection among the donor sheep may be the result of a protective 
effect of codon 154 heterozygosity to oral challenge with BSE, although more data 
are required to confirm this association.  
 
A novel polymorphism, resulting in a proline to leucine substitution at codon 168 of 
the PrP gene, was identified in four BSE transfusion recipients and two positive 
control sheep inoculated intravenously with BSE14. All six survived >2000 days 
without developing clinical signs of BSE, but on post mortem examination four 
showed PrPSc deposition in brain and lymphoid tissues. This suggests that the P168L 
polymorphism can protect against clinical disease, but does not prevent infection by 
the intravenous route. This polymorphism has not been identified in the Edinburgh 
NPU Cheviots used as donors in the BSE experiment, nor in sheep with the 
VRQ/VRQ genotype.  
 
Although the genetic basis of susceptibility to BSE infection in sheep and humans is 
not directly comparable, the variability in response to BSE found in ARQ/ARQ sheep  
provides a more realistic reflection of the situation with vCJD in the human 
population than the very uniform susceptibility of VRQ/VRQ sheep to scrapie 
infection. In addition, the survival of BSE-infected transfusion recipients for up to 7 
years without clinical signs demonstrates that prolonged secondary incubation periods 
and/or a sub-clinical/“carrier” state are possible following transfusion in sheep. The 
existence of such sub-clinical or prolonged pre-clinical infection states in humans is 
recognised as one of the important factors influencing the probability of onward 
transmission, and thus the potential size of the vCJD epidemic29. Susceptibility to 
human TSEs has been linked to codon 129 of the PrP gene, which can encode either 
methionine (M) or valine (V). Until recently, all clinical cases of vCJD (including the 
3 transfusion-related cases) that have been tested have been homozygous for 
methionine at 129 (129MM). Interestingly, the “pre-clinical” individual believed to 
have been infected by transfusion was heterozygous (129MV)21. There is 
accumulating evidence to suggest that all human 129 genotypes may be susceptible to 
vCJD infection, with apparently greater likelihood of sub-clinical infection in 129MV 
and 129VV individuals30-32.  
 
3) Effect of blood component. 
 
The four transfusion-related vCJD infections occurred in individuals who received 
transfusions of red cells that had not been leucodepleted. Leucodepletion was 
introduced in the UK in 1999 to control the risk of transmission of vCJD by blood 
transfusion, because previous studies in rodents had shown that infectivity appeared to 
be concentrated in the buffy coat, which contains most of the blood leukocytes4. 
Subsequently, leucodepletion of blood from scrapie-infected hamsters was shown to 
remove up to 72% of infectivity33,34. In the sheep experiments, only whole blood and 
buffy coat were transfused, because we were seeking to establish proof of principle of 
transmission of TSEs by blood transfusion, and assessing whether infectivity 
appeared to be concentrated in the buffy coat. The effect of leucodepletion was not 
investigated, but is being addressed in a follow-up study, along with estimates of the 
distribution of infectivity among other blood components, including plasma, platelets 
and red cells.  
 
In our experiments, transmission rates did not appear to be significantly different in 
recipients receiving whole blood compared to recipients transfused with buffy coat. 
The number of sheep transfused with buffy coat in the BSE experiment was too small 
to allow statistical analysis. In the scrapie experiment, five of the positive recipients 
were transfused with buffy coat, and four with whole blood.  The similarity in 
transmission rates for both components suggests that they contain approximately 
equivalent amounts of infectivity.   
 
We have shown that, for sheep infected with scrapie and BSE, high transmission rates 
can be achieved using blood transfusion, particularly when donors are at >50% of 
incubation period. The results also revealed the possibility of prolonged incubation 
periods and/or sub-clinical infections in some recipients of BSE-infected blood, which 
is at least partly due to genetic variation in the sheep PrP gene. The suggestion of 
relatively high titres of infectivity in blood is perhaps surprising in view of the need 
for ultra-sensitive methods of detection for PrPSc in blood35,36. It may be that, in 
blood, infectivity is not closely correlated with levels of protease-resistant PrP, but 
comparative titrations of brain and blood-borne infectivity in sheep will be required to 
further define the relationship. The results of our sheep transfusion experiments are 
consistent with what is known about transfusion-associated vCJD transmission in 
man, and support the use of sheep as an experimental model in which to study the 
risks associated with different blood products, the effectiveness of control measures 
and the development of diagnostic and screening tests. 
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Figure 1. Overview of experimental design. 
 
Figure 2. Outcome of transfusions as a function of the stage of disease incubation 
in the donor. A. BSE-infected donors. B. Scrapie-infected donors. For each stage of 
infection in the donor sheep, the number of uninfected (open bars), clinically positive/ 
IHC positive (solid bars) and clinically negative/IHC positive (cross-hatched bars) 
recipients are shown.  
 
Table 1. Outcome of transfusions from BSE-exposed donor sheep. 
 
Key: WB = d, BC  coat, D dorsal ro  ganglion, P = ileal ’s patch  whole bloo  = buffy RG = ot  IP  Peyer
Donor sheep details Recipient sheep details 
Donor 
sheep 
ID 
Donor 
genotype 
Clinical 
status at 
donation 
% actual 
or average 
incubation 
period at 
donationa
Clinical 
outcome 
IHC 
result  
Incubation 
period 
(days) 
Component 
transfused 
Recipient 
sheep ID 
Recipient 
PrP 168 
codon 
genotype 
Clinical 
outcome 
IHC 
result  
Incubation 
period 
(days) 
58x51           ARQ/ARQ Preclinical 12 + + 2131 WB D529 PP +c - -
22 WB PLD433    - --60x49     
      
ARQ/ARQ Preclinical
 44 
- +/-
(DRG)b
- 
WB F14 PL - - -
42 BC PPF182    - --J2747      
      
ARQ/AHQ Preclinical
 44 
- - -
WB F181 PP - - -
42 BC PPF238    +c - -61x24      
      
ARQ/AHQ Preclinical
Preclinical 43 
- - -
WB F234 PP - - -
J2746             AHQ/AHQ Preclinical 45 - - - WB F19 PP + + 536
J2559             AHQ/AHQ Preclinical 51 + + 629 WB D505 PP + + 610
58x81            ARQ/AHQ Preclinical 61 - +/-
(IPP)b
- BC D358 PP - - -
61 WB PPD421    - --58x28      
      
ARQ/AHQ Preclinical
 61 
- - -
BC D384 PP - - -
61 WB PPD452  - - +d58x27      
      
AHQ/AHQ Preclinical
 61 
- - -
BC D318 PP - - -
62 WB PPD337  - - +e58x39      
      
ARQ/AHQ Preclinical
 62 
- - -
WB D386 PP - - -
J2499             AHQ/AHQ Preclinical 86 + + 761 WB D341 PP - - -
J2771            AHQ/AHQ Clinical 100 + + 561 BC G61 PL - + -
J2770             AHQ/AHQ Clinical 100 + + 589 WB G74 PP + + 594
WB      G78 PP + + 55660x69       
      
AHQ/AHQ Clinical
 
100 + + 660
BC G49 PP + + 531
D383             ARQ/ARQ Clinical 100 + + 671 WB G92 PL - + -
a Calculated from the days post-infection at the time of donation, as a percentage either of the final incubation period (in sheep kept alive until the development of clinical 
signs), or of the average incubation period in orally-infected donors (640 days), excluding the out-lying incubation period of 2131 days for 58x51. 
bThese tissues were initially scored weakly positive by IHC, but the results were not reproducible in two laboratories and can therefore be considered as inconclusive. 
cNo evidence of infection was found on post mortem examination of tissues from these clinical suspects; therefore it is most likely they were clinically misdiagnosed. 
dThis sheep died of unrelated causes (i.e. without showing clinical signs of BSE) at 1139 days post transfusion, but was positive by IHC.  
e This apparently healthy sheep was culled 3018 days post transfusion and found to be positive by IHC; however further analysis suggested this was a case of “atypical” 
scrapie, and therefore unlikely to be transfusion related (see text for details). 
 
Table 2: Outcome of transfusions from scrapie-exposed donor sheep 
 
a Calculated fro h  donation percentag her of the f al incubatio iod (for sh  that surv til the dev opment of clinical signs), 
the average incubation period (1296 days) for sheep that died or were culled before developing clinical signs. 
m the age at t e time of , as a e eit in n per eep ived un el or of 
Donor sheep details Recipient sheep details 
Donor 
sheep ID 
Donor 
genotype 
Clinical 
status at 
donation 
% actual 
or average 
incubation 
period at 
donationa
Clinical 
outcome 
IHC result Incubation 
period 
(days) 
Component 
transfused 
Recipient 
sheep ID 
Clinical 
outcome 
IHC result Incubation 
period 
(days) 
17 BC -G247 - -  67x42      
     
VRQ/VRQ Preclinical
19 
+ + 1274
WB G230 - - -
17 WB -G267 -   -66x45      
     
VRQ/VRQ Preclinical
19 
- - -
BC G265 - - -
18 BC -G241 - -  67x23      
     
VRQ/VRQ Preclinical
20 
+ + 1207
WB G228 - - -
28 WB -F275 -   -65x13      
     
VRQ/VRQ Preclinical
30 
+ + 1556
BC F273 - - -
34 WB -F310 -   -65x02      
     
VRQ/VRQ Preclinical
37 
- + -
BC F309 + + 1101
34 WB +F277 + 1138  65x03      
    
VRQ/VRQ Preclinical
37 
- + -
BC F276 +b - -
53 BC +F149 + 782  61x75      
     
VRQ/ARQ Preclinical
57 
+ + 1324
WB F144 + + 672
64 BC +F152 + 853  61x68      
     
VRQ/VRQ Preclinical
69 
+ + 1113
WB F153 + + 660
62 WB -F286 -   -61x66      
     
VRQ/VRQ Preclinical
64 
- ND -
BC F284 - - -
73 BC +F126 + 826  59x27      
     
VRQ/VRQ Preclinical
77 
+ + 1137
WB F141 + + 575
59x28            VRQ/VRQ Clinical 100 + + 1081 BC F143 + + 737
bNo evidence of infection was found on post mortem examination of tissues from this clinical suspect; therefore it is most likely it was clinically misdiagnosed. 
 
